Page last updated: 2024-08-24

topotecan and binimetinib

topotecan has been researched along with binimetinib in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Aghajanian, C; Banerjee, S; Berger, R; Boyd, AP; Christy-Bittel, J; Churruca, C; Cibula, D; Clamp, A; Coleman, RL; Colombo, N; Del Campo, JM; Drill, E; Grisham, RN; Hilpert, F; Kalbacher, E; Kristensen, G; Marth, C; Mirza, MR; Monk, BJ; Moore, KN; O'Malley, DM; Oehler, MK; Oza, AM; Pignata, S; Ray-Coquard, I; Romero, I; Sehouli, J; Vergote, I; Vuylsteke, P; Westermann, A1

Trials

1 trial(s) available for topotecan and binimetinib

ArticleYear
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 11-10, Volume: 38, Issue:32

    Topics: Adult; Aged; Benzimidazoles; Cystadenocarcinoma, Serous; Doxorubicin; Fallopian Tube Neoplasms; Female; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols; Progression-Free Survival; Protein Kinase Inhibitors; Topotecan; Young Adult

2020